Cargando…

Intra-arterial chemotherapy in locally advanced or recurrent carcinomas of the penis and anal canal: an active treatment modality with curative potential

The prognosis of locally advanced or recurrent carcinomas of the penis (PE) and of the anal canal (AC) after conventional treatment is dismal. We report 16 patients (eight with AC carcinomas and eight with PE cancers) treated by intra-arterial (IA) chemotherapy. Fifteen of them were treated for loca...

Descripción completa

Detalles Bibliográficos
Autores principales: Roth, A D, Berney, C R, Rohner, S, Allal, A S, Morel, P, Marti, M-C, Aapro, M S, Alberto, P
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2000
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363463/
https://www.ncbi.nlm.nih.gov/pubmed/11104558
http://dx.doi.org/10.1054/bjoc.2000.1525
_version_ 1782153711099838464
author Roth, A D
Berney, C R
Rohner, S
Allal, A S
Morel, P
Marti, M-C
Aapro, M S
Alberto, P
author_facet Roth, A D
Berney, C R
Rohner, S
Allal, A S
Morel, P
Marti, M-C
Aapro, M S
Alberto, P
author_sort Roth, A D
collection PubMed
description The prognosis of locally advanced or recurrent carcinomas of the penis (PE) and of the anal canal (AC) after conventional treatment is dismal. We report 16 patients (eight with AC carcinomas and eight with PE cancers) treated by intra-arterial (IA) chemotherapy. Fifteen of them were treated for locally advanced or recurrent disease and one in an adjuvant setting. The chemotherapy was administered via a femoral IA catheter with its tip located above the aortic bifurcation, under the inferior mesenteric artery. It consisted of eight push injections, given over a 48-h period, of the following drug combination: cisplatin 8.5 mg m(–2), 5-FU 275 mg m(–2), methotrexate 27.5 mg m(–2), mitomycin C 1.2 mg m(–2), and bleomycin 4 mg m(–2). Leucovorin was given po, 4 × 15 mg day(–1), during the chemotherapy and for 3 days thereafter. A total of 52 cycles of treatment were administered. Of the 15 patients evaluable for response, six obtained a CR (three PE, three AC) and eight a PR. Among the complete responders, four are alive and disease-free 2–15 years after treatment. The other patients enjoyed an objective response lasting 3–25 months (median 7 months). Four patients developed grade III/IV haematological toxicity with three episodes of febrile neutropenia, one of them with a fatal outcome due to patient's failure to obtain medical attention at the onset of his fever, one a grade III mucositis of the glans, and four a grade III/IV cutaneous toxicity, the latter caused by the IA administration of bleomycin. In conclusion, IA chemotherapy is effective and potentially curative in locoregionally advanced or recurrent carcinomas of the penis and of the anus. Its contribution in the primary management of advanced penile or anal carcinoma should be prospectively investigated. © 2000 Cancer Research Campaign http://www.bjcancer.com
format Text
id pubmed-2363463
institution National Center for Biotechnology Information
language English
publishDate 2000
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-23634632009-09-10 Intra-arterial chemotherapy in locally advanced or recurrent carcinomas of the penis and anal canal: an active treatment modality with curative potential Roth, A D Berney, C R Rohner, S Allal, A S Morel, P Marti, M-C Aapro, M S Alberto, P Br J Cancer Regular Article The prognosis of locally advanced or recurrent carcinomas of the penis (PE) and of the anal canal (AC) after conventional treatment is dismal. We report 16 patients (eight with AC carcinomas and eight with PE cancers) treated by intra-arterial (IA) chemotherapy. Fifteen of them were treated for locally advanced or recurrent disease and one in an adjuvant setting. The chemotherapy was administered via a femoral IA catheter with its tip located above the aortic bifurcation, under the inferior mesenteric artery. It consisted of eight push injections, given over a 48-h period, of the following drug combination: cisplatin 8.5 mg m(–2), 5-FU 275 mg m(–2), methotrexate 27.5 mg m(–2), mitomycin C 1.2 mg m(–2), and bleomycin 4 mg m(–2). Leucovorin was given po, 4 × 15 mg day(–1), during the chemotherapy and for 3 days thereafter. A total of 52 cycles of treatment were administered. Of the 15 patients evaluable for response, six obtained a CR (three PE, three AC) and eight a PR. Among the complete responders, four are alive and disease-free 2–15 years after treatment. The other patients enjoyed an objective response lasting 3–25 months (median 7 months). Four patients developed grade III/IV haematological toxicity with three episodes of febrile neutropenia, one of them with a fatal outcome due to patient's failure to obtain medical attention at the onset of his fever, one a grade III mucositis of the glans, and four a grade III/IV cutaneous toxicity, the latter caused by the IA administration of bleomycin. In conclusion, IA chemotherapy is effective and potentially curative in locoregionally advanced or recurrent carcinomas of the penis and of the anus. Its contribution in the primary management of advanced penile or anal carcinoma should be prospectively investigated. © 2000 Cancer Research Campaign http://www.bjcancer.com Nature Publishing Group 2000-12 /pmc/articles/PMC2363463/ /pubmed/11104558 http://dx.doi.org/10.1054/bjoc.2000.1525 Text en Copyright © 2000 Cancer Research Campaign https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Regular Article
Roth, A D
Berney, C R
Rohner, S
Allal, A S
Morel, P
Marti, M-C
Aapro, M S
Alberto, P
Intra-arterial chemotherapy in locally advanced or recurrent carcinomas of the penis and anal canal: an active treatment modality with curative potential
title Intra-arterial chemotherapy in locally advanced or recurrent carcinomas of the penis and anal canal: an active treatment modality with curative potential
title_full Intra-arterial chemotherapy in locally advanced or recurrent carcinomas of the penis and anal canal: an active treatment modality with curative potential
title_fullStr Intra-arterial chemotherapy in locally advanced or recurrent carcinomas of the penis and anal canal: an active treatment modality with curative potential
title_full_unstemmed Intra-arterial chemotherapy in locally advanced or recurrent carcinomas of the penis and anal canal: an active treatment modality with curative potential
title_short Intra-arterial chemotherapy in locally advanced or recurrent carcinomas of the penis and anal canal: an active treatment modality with curative potential
title_sort intra-arterial chemotherapy in locally advanced or recurrent carcinomas of the penis and anal canal: an active treatment modality with curative potential
topic Regular Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363463/
https://www.ncbi.nlm.nih.gov/pubmed/11104558
http://dx.doi.org/10.1054/bjoc.2000.1525
work_keys_str_mv AT rothad intraarterialchemotherapyinlocallyadvancedorrecurrentcarcinomasofthepenisandanalcanalanactivetreatmentmodalitywithcurativepotential
AT berneycr intraarterialchemotherapyinlocallyadvancedorrecurrentcarcinomasofthepenisandanalcanalanactivetreatmentmodalitywithcurativepotential
AT rohners intraarterialchemotherapyinlocallyadvancedorrecurrentcarcinomasofthepenisandanalcanalanactivetreatmentmodalitywithcurativepotential
AT allalas intraarterialchemotherapyinlocallyadvancedorrecurrentcarcinomasofthepenisandanalcanalanactivetreatmentmodalitywithcurativepotential
AT morelp intraarterialchemotherapyinlocallyadvancedorrecurrentcarcinomasofthepenisandanalcanalanactivetreatmentmodalitywithcurativepotential
AT martimc intraarterialchemotherapyinlocallyadvancedorrecurrentcarcinomasofthepenisandanalcanalanactivetreatmentmodalitywithcurativepotential
AT aaproms intraarterialchemotherapyinlocallyadvancedorrecurrentcarcinomasofthepenisandanalcanalanactivetreatmentmodalitywithcurativepotential
AT albertop intraarterialchemotherapyinlocallyadvancedorrecurrentcarcinomasofthepenisandanalcanalanactivetreatmentmodalitywithcurativepotential